10x Genomics director granted 8,829 RSUs

Popovits Kimberly J reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Popovits Kimberly J reported acquisition or exercise transactions in this Form 4 filing.

10x Genomics director Kimberly J. Popovits received an equity award in the form of restricted stock units. She was granted 8,829 RSUs, each representing one share of Class A Common Stock at no cash cost, bringing her direct holdings to 37,445 shares. One quarter of the RSUs will vest on each quarterly anniversary starting from May 21, 2026, as long as she continues as a service provider on those dates.

Insider Trade Summary

Grant/Award: 8,829 shares

Grant/Award 1 txn

Insider Popovits Kimberly J

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Class A Common Stock	8,829	$0.00	$0.00

Holdings After Transaction: Class A Common Stock — 37,445 shares (Direct)

Footnotes (1)

1. F1. Constitute restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Class A Common Stock upon vesting. 1/4th of the RSUs shall vest on each quarterly anniversary measured from May 21, 2026, subject to the Reporting Person continuing as a service provider through each such date.

Key Figures

RSU grant size: 8,829 RSUs Price per share: $0.0000 per share Total shares after grant: 37,445 shares +2 more

5 metrics

RSU grant size 8,829 RSUs Grant of restricted stock units to director on June 4, 2026

Price per share $0.0000 per share Reported transaction price for RSU award

Total shares after grant 37,445 shares Director’s direct Class A Common Stock holdings post-transaction

Vesting start reference date May 21, 2026 Quarterly vesting measured from this date

Vesting pattern 1/4 each quarter Quarterly vesting of RSUs over four installments

Key Terms

restricted stock units ("RSUs"), Class A Common Stock, contingent right, service provider

4 terms

restricted stock units ("RSUs") financial

"Constitute restricted stock units ("RSUs"). Each RSU represents a contingent right..."

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

Class A Common Stock financial

"Each RSU represents a contingent right to receive one share of Class A Common Stock..."

Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.

contingent right financial

"Each RSU represents a contingent right to receive one share of Class A Common Stock..."

service provider financial

"...subject to the Reporting Person continuing as a service provider through each such date."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did 10x Genomics (TXG) director Kimberly Popovits report on this Form 4?

Kimberly Popovits reported receiving 8,829 restricted stock units of 10x Genomics Class A Common Stock. These RSUs are an equity award, not an open-market purchase or sale, and increase her direct holdings to 37,445 shares following the grant.

How many 10x Genomics (TXG) shares were granted to the director in this filing?

The director received 8,829 restricted stock units, each equal to one share of Class A Common Stock. This equity grant brought her total direct holdings after the transaction to 37,445 shares, according to the share balance reported in the Form 4.

What is the vesting schedule for the 10x Genomics (TXG) RSUs granted to Kimberly Popovits?

The 8,829 RSUs vest in four equal installments, with one quarter vesting on each quarterly anniversary from May 21, 2026. Vesting is contingent on Kimberly Popovits continuing as a service provider to 10x Genomics on each scheduled vesting date.

Did Kimberly Popovits buy or sell 10x Genomics (TXG) shares in the market?

No market buy or sell occurred; the Form 4 reports a grant classified as an acquisition. The 8,829 shares were received as restricted stock units with a reported price per share of $0.0000, indicating a compensation award rather than a market transaction.

How does this RSU grant affect Kimberly Popovits’s ownership in 10x Genomics (TXG)?

After receiving 8,829 restricted stock units, Kimberly Popovits’s direct holdings total 37,445 shares of Class A Common Stock. The RSUs will convert into shares over time as they vest, assuming she continues providing services to the company.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/08/2026 - 07:25 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Popovits Kimberly J

(Last) (First) (Middle)

C/O 10X GENOMICS, INC.

6230 STONERIDGE MALL ROAD

(Street)

PLEASANTON CALIFORNIA 94588

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
10x Genomics, Inc. [ TXG ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	06/04/2026		A		8,829(1)	A	$0	37,445	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Constitute restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Class A Common Stock upon vesting. 1/4th of the RSUs shall vest on each quarterly anniversary measured from May 21, 2026, subject to the Reporting Person continuing as a service provider through each such date.

Remarks:

Exhibit 24.1 - Power of Attorney

	/s/ Randy Wu, as Attorney-in-Fact for Kimberly J. Popovits	06/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)